Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

665 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liégeois F, Nerrienet E, Tardy M, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngolé E, Delaporte E. Laurent C, et al. Among authors: calmy a. Lancet. 2004 Jul 3-9;364(9428):29-34. doi: 10.1016/S0140-6736(04)16586-0. Lancet. 2004. PMID: 15234853 Clinical Trial.
Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon.
Kouanfack C, Laurent C, Peytavin G, Ciaffi L, Ngolle M, Nkene YM, Essomba C, Calmy A, Mpoudi-Ngolé E, Delaporte E, Koulla-Shiro S; French National Agency for Research on AIDS 1274 Study Group. Kouanfack C, et al. Among authors: calmy a. J Acquir Immune Defic Syndr. 2008 Jun 1;48(2):216-9. doi: 10.1097/QAI.0b013e3181743955. J Acquir Immune Defic Syndr. 2008. PMID: 18520681 Free article.
A new era of antiretroviral drug toxicity.
Calmy A, Hirschel B, Cooper DA, Carr A. Calmy A, et al. Antivir Ther. 2009;14(2):165-79. doi: 10.1177/135965350901400203. Antivir Ther. 2009. PMID: 19430091 Review.
Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
Calmy A, Vallier N, Nguyen A, Lange JM, Battegay M, de Wolf F, Reiss P, Lima VD, Hirschel B, Hogg RS, Yip B, Montaner JS, Wit FW; Swiss HIV Cohort study; HAART Observational Medical Evaluation and Research Cohort; Netherlands ATHENA Observational Cohort. Calmy A, et al. Antivir Ther. 2009;14(7):931-8. doi: 10.3851/IMP1418. Antivir Ther. 2009. PMID: 19918097
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
Mbougua JB, Laurent C, Kouanfack C, Bourgeois A, Ciaffi L, Calmy A, Gwet H, Koulla-Shiro S, Ducos J, Mpoudi-Ngolé E, Molinari N, Delaporte E. Mbougua JB, et al. Among authors: calmy a. BMC Public Health. 2010 Mar 1;10:105. doi: 10.1186/1471-2458-10-105. BMC Public Health. 2010. PMID: 20193053 Free PMC article.
665 results